Brain network topology and its cognitive impact in adult glioma survivors, from @LaurienDeRoeck, @mlambr1, @CharlotteSleurs, @treanus, Jeroen Blommaert, and Patrick Dupont
https://t.co/Zy0EUw4VWi
📢 our latest research published in @Nature Sci Rep 🧠
https://t.co/fohb41pYub
Our study reveals how structural brain network metrics are altered in glioma survivors and how these changes are linked to cognitive functions.
@mlambr1 @CharlotteSleurs @treanus
@drdavidpalma @SchneidersFamke Adding to the congratulory comments @drdavidpalma. Your leadership and insight in this trial and space is tremendous.
Looking forward to seeing results from this Herculean effort.
#ASTRO2023
Assessment of Precision RT in Early NSCLC and ILD (ASPIRE-ILD) presented by @drdavidpalma
👉 OS at 1-year 78.9%, median OS 25 months
👉 AE event: grade 3 n=4 (10%), grade 4 n=0, grade 5 n=3 (7.7%)
👍 Primary endpoint met, SBRT valid option in overall high-risk pts
#ASTRO2023
High Dose Hyperfractionated Thoracic RT vs. Standard Dose for LS SCLC: Randomized Phase 3 Trial
45Gy in 30 FX vs 54Gy in 30FX
👉 Substantial difference in OS, smaller but significant in PFS
👉 Similar toxicity
❓ Difference in effect size OS vs PFS
❓ Pt selection
In UZ Leuven werd voor het eerst een patiënt op het hart bestraald om levensbedreigende ritmestoornissen te verhelpen. Prof. @EctorJoris: "De samenwerking tussen cardiologen en radiotherapeuten biedt onze patiënten een bijkomende behandelingsoptie."
👉 https://t.co/jN8pr9bhD0
Single fraction 8Gy vs SBRT 20Gy for painful bone mets, n=126, mostly non-spine #ESTRO23
Complete pain response at 1 mo primary endpoint
👉 no difference at 1 mo
👉 improved in per protocol analysis after 3mo
👉 no increased toxicity
PATIENT SELECTION IS KEY
OMD requires optimal local & systemic Tx: safe combo of SBRT with novel drugs ?
👉 Consensus about risk mitigation strategies:
❓Same day Tx
❓Interruption or delay of systemic Tx
❓Adaptation of RT dose / fractionation
From @ESTRO_RT & @EORTC#OligoCare
https://t.co/QOhUHL0oca
@ErinGillespieMD presents a provocative phase II RCT of prophylactic #radiotherapy to asymptomatic but high risk bone Mets. N=93 Convincing home run, 29% vs 1.6% skeletal related events, with an ⬆️ OS benefit! Remained significant on MVA #ASTRO22#OncoAlert
Goed nieuws in @destandaard vandaag: 6 ziekenhuizen krijgen gespecialiseerde teams voor kankerpatiënten van 16 tot 35 jaar. Met jaarlijks 250 diagnoses investeert @UZLeuven volop in zorg voor jongeren met kanker: https://t.co/rjxMzz67qn @komop_tgkanker
https://t.co/943Lmu20D4